AB
Antlia Bioscience, Inc.
The startup develops peptide-based therapies using its proprietary PASylation platform to modify pharmacokinetics and create long-acting analogs. This approach provides healthcare providers with effective treatment options for chronic cardiovascular, metabolic, and endocrine diseases based on established biological mechanisms.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$890KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops peptide-based therapies using its proprietary PASylation platform to modify pharmacokinetics and create long-acting analogs. This approach provides healthcare providers with effective treatment options for chronic cardiovascular, metabolic, and endocrine diseases based on established biological mechanisms.